Dear Sir,

Clearly, to allow appropriate resource planning, trends in clinical practice need to be recognised and acted upon.

In the field of spinal surgery, the management of metastatic spinal disease has significantly changed over the years. Surgical techniques have improved and patient survival is increasing. The Patchell papere[@b1] demonstrated an advantage in clinical outcomes for patients undergoing surgery followed by radiotherapy. NICE guidelines for malignant spinal cord compression (MSCC)[@b2] promoted spinal surgical input. Improved medical and oncological treatments are leading to increased survival times.

We recently reviewed the fracture outcome research database (FORD) for the last 10 years to assess if our impression of an increasing demand for surgery was real or perceived.

The results are startling.

Of the 3468 patients admitted to the RVH trauma unit in 2000, 351 were spinal admissions of various causes. By 2010, the total number of admissions for general fractures had remained relatively static at 3483, but the number of spinal admissions had increased to 650. 18 patients underwent surgery in 2000 for MSCC, whereas an exponential rise in numbers lead to 78 patients being operated on in 2010 for MSCC ([table 1](#tbl1){ref-type="table"}, [graph 1](#fig1){ref-type="fig"}). Fractures of the spine undergoing surgery showed no significant increase.
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             year     2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010
  ---------- -------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Number     Tumour   18     17     17     32     28     26     25     30     33     33     78
  Fracture   292      352    348    306    279    326    299    326    303    339    357    

The impact of this increase is twofold. These patients undergo complex surgery taking significant theatre time often displacing other work and the operations these patients undergo require expensive implants. However, the effect of this surgery for the patient is often significant. Whilst survival time may or may not increase, quality of life is significantly improved and the demand for this surgery will not go away in the short term.

This trend will in all probability continue and the impact on time and financial budgets will continue to increase. With advances in medical oncology, the demand will in all likelihood eventually plateau, but as yet we have not reached such a point.

From a managerial perspective, it needs to be clearly understood that this patient group quite rightly will continue to place an increasing financial and time burden on our service. Unlike other conditions, time is of the essence by definition and it will be hard if not impossible to restrict this budget demand.
